ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

1.98
0.02
(1.02%)
Closed November 21 4:00PM
1.98
0.00
( 0.00% )
Pre Market: 6:05AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.98
Bid
1.98
Ask
2.01
Volume
-
0.00 Day's Range 0.00
1.50 52 Week Range 8.33
Market Cap
Previous Close
1.98
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,226,570
Shares Outstanding
90,552,687
Dividend Yield
-
PE Ratio
-1.76
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $1.98. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.50 to $ 8.33.

Caribou Biosciences currently has 90,552,687 shares outstanding. The market capitalization of Caribou Biosciences is $179.29 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.76.

CRBU Latest News

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...

Caribou Biosciences Reports Third Quarter 2024 Financial Results andΒ  Provides Business Update

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after...

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.07-3.414634146342.052.121.9115501961.97809015CS
40.126.451612903231.862.99951.7719110582.28513789CS
12-0.14-6.603773584912.122.99951.6312265702.11250498CS
26-1.12-36.12903225813.13.191.516906752.12440219CS
52-3.39-63.12849162015.378.331.517006103.69325419CS
156-19.92-90.958904109621.921.91.512821815.54552334CS
260-15.67-88.781869688417.6532.6451.512272306.61143236CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WCTWellchange Holdings Company Limited
$ 2.37
(89.60%)
12.56M
VRPXVirpax Pharmaceuticals Inc
$ 0.9533
(61.66%)
11.85M
SJWSJW Group
$ 87.99
(58.97%)
40
NSTSNSTS Bancorp Inc
$ 17.72
(58.36%)
8
IMOSChipMOS Technologies Inc
$ 27.99
(44.28%)
4
KELYAKelly Services Inc
$ 7.11
(-48.92%)
1
ENTAEnanta Pharmaceuticals Inc
$ 5.01
(-46.19%)
117
FNWBFirst Northwest Bancorp
$ 6.01
(-45.71%)
1
WAFDWaFd Inc
$ 21.82
(-39.97%)
28
KSCPKnightscope Inc
$ 11.08
(-39.42%)
13.69k
WCTWellchange Holdings Company Limited
$ 2.37
(89.60%)
12.56M
VRPXVirpax Pharmaceuticals Inc
$ 0.9533
(61.66%)
11.85M
BENFBeneficient
$ 1.10
(25.00%)
8.1M
RGTIRigetti Computing Inc
$ 1.78
(20.27%)
7.06M
SKKSKK Holdings Limited
$ 1.42
(29.09%)
4.44M

CRBU Discussion

View Posts
TrendTrade2016 TrendTrade2016 2 weeks ago
CRBU READY TO BEAST
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 3 weeks ago
CRBU...NEW SCAN JUST GAVE ME THIS BIO
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
CRBU under $3
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
CRBU under $2
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
CRBU under $3
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
CRBU under $3
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
CRBU under $3
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
CRBU new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
CRBU new 52 week low
πŸ‘οΈ0
NY1972 NY1972 5 months ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
πŸ‘οΈ0
Diego Rivas Diego Rivas 6 months ago
Any good news in here comming?
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
CRBU new 52 week low
πŸ‘οΈ0
stocksrising stocksrising 6 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 6 months ago
CRBU new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
CRBU new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
CRBU under $5
πŸ‘οΈ0
stocksrising stocksrising 8 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CRBU new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
πŸ‘οΈ0
trueblue trueblue 1 year ago
.
πŸ‘οΈ0
trueblue trueblue 1 year ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
πŸ‘οΈ0
NY1972 NY1972 1 year ago
Didn't they buy TRIL? Just gambling with billions from US government.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
πŸ‘οΈ0
trueblue trueblue 1 year ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
trueblue trueblue 1 year ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 1 year ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock